Teplizumab

The drug, tepluzimab, an anti-CD3 antibody, has now been approved by the U.S. Food and Drug Administration (FDA) for children and adults with preclinical type 1 diabetes. A 14-day intravenous course of teplizumab has been shown to be capable of slowing the course of onset of type 1 diabetes. Tepluzimab is not currently licensed in the UK and will need to be assessed and approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and National Institute for Health and Care Excellence (NICE) before it becomes available.

References

1. Sims EK, et al; Type 1 Diabetes TrialNet Study Group. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci Transl Med. 2021 Mar 3;13(583):eabc8980.
2. Herold KC, et al; Type 1 Diabetes TrialNet Study Group. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med. 2019 Aug 15;381(7):603-613. doi: 10.1056/NEJMoa1902226. Epub 2019 Jun 9. Erratum in: N Engl J Med. 2020 Feb 6;382(6):586.